Conatus Pharmaceuticals Inc. (CNAT)
| Market Cap | 18.44M |
| Revenue (ttm) | 14.69M |
| Net Income (ttm) | -10.12M |
| Shares Out | 33.17M |
| EPS (ttm) | -0.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 26, 2020 |
| Last Price | $0.556 |
| Previous Close | $0.556 |
| Change ($) | 0.000 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 0.541 - 0.594 |
| Day's Volume | 1,696,913 |
| 52-Week Range | 0.230 - 1.070 |
News
SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today...
SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today...
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today convened and adjourned its special meeting of stockholders in order to obtain a quorum and specif...
SAN DIEGO, April 20, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced tod...
SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced tod...
Proposed Merger Creates Regenerative Medicine Company with Three Clinical-stage Product Candidates and Combined Company Capitalization Expected to Support Operations into 2021
NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an addition...
Conatus (CNAT) delivered earnings and revenue surprises of 16.67% and -48.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conatus (CNAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.
Conatus (CNAT) delivered earnings and revenue surprises of 83.33% and 54.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conatus' (CNAT) emricasan fails to meet the primary endpoint in the phase IIb ENCORE-LF study on decompensated NASH cirrhosis patients while the ENCORE-PH probe falls shy of the predefined obj...
Shares of micro-cap biotech Conatus Pharmaceuticals Inc (NASDAQ: CNAT) were sinking further into penny stock territory Tuesday after two announcements made Monday after the market close.
Conatus (CNAT) reported earnings 30 days ago. What's next for the stock?
Conatus' (CNAT) lead candidate, emricasan, developed for treating patients with fibrosis or cirrhosis caused by NASH misses the primary endpoint in two mid-stage studies that hits the stock ma...
Conatus, (CNAT) earnings and revenues lag estimates in the first-quarter of 2019. Emricasan remains in focus.
Conatus (CNAT) delivered earnings and revenue surprises of -16.67% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conatus (CNAT) reported earnings 30 days ago. What's next for the stock?
NASH is a highly lucrative market with blockbuster potential. Let us take a look at the winners and losers in this space so far in 2019.
Conatus' (CNAT) stock plunges as the phase IIb study on emricasan for the treatment of biopsy-confirmed NASH and liver fibrosis fails.
Shares of microcap biotech Conatus Pharmaceuticals Inc. are heading crashing following the release of results from a midstage trial of its non-alcoholic steatohepatitis candidate.
Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.
Conatus (CNAT) makes an improvement with narrower-than-expected loss in the fourth quarter of 2018. Also, revenues beat mark.
About CNAT
Conatus Pharmaceuticals, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing C... [Read more...]
| Industry Biotechnology | IPO Date Jul 25, 2013 |
| CEO Steven J. Mento | Employees 5 |
| Stock Exchange NASDAQ | Ticker Symbol CNAT |